secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001104659-24-045577
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma reports preliminary Phase 1 data for CT-0508; 40.7% target lesion reduction in monotherapy
--------------------------------------------------------------------------------

- In 14 monotherapy patients, 40.7% of target lesions reduced in size on ≥1 scan across all anatomic sites.
- Combination sub-study of CT-0508 with pembrolizumab enrolled 6 patients; data from first 3 shown.
- First two combination patients received corticosteroids prior to pembro; both had progressive disease as best response.
- Third combination patient achieved stable disease with 46% reduction in one target lesion; PD due to new brain met.
- Company notes corticosteroids may reverse CT-0508 activity based on in vitro cell death data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924045577/0001104659-24-045577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924045577/tm2411506d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-045577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer